anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: CLODRONIC ACID
Trial phase: Not Applicable
ATC code: M05BA02
SMILES: O=P(O)(O)C(Cl)(Cl)P(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Intravesical instillation of Liposomes in sterile water totally 40 cc at four weekly treatments.
Eligibility criteria:
Inclusion Criteria:

Ulcerative IC for at least 6 months documented,
Negative urine cytology,
Able to independently complete self administered questionnaires and voiding diaries.

Exclusion Criteria:

Pregnant or lactating,
History of bleeding diathesis,
On anticoagulant therapy,
Active peptic ulcer disease,
Obvious neurological impairment,
Known allergy to liposomes.
Intervention: Linagliptin
Trial phase: Phase 3
ATC code: A10BD11 | A10BD19 | A10BD27 | A10BH05
SMILES: CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 162
Group description: Patients randomized to receive treatment with Linagliptin 5mg
Eligibility criteria:
Inclusion criteria:

Type 2 diabetes mellitus
HbA1c >= 7.0%
Age >= 70 years
Signed and dated written informed consent

Exclusion criteria:

Myocardial infarction, stroke or TIA within 3 months prior to informed consent
Impaired hepatic function
Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors or rapid acting or pre-mixed insulins
Treatment with anti-obesity drugs
Intervention: Colchicine
Trial phase: Phase 4
ATC code: M04AC01
SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Healthy participants with normal renal function (Creatinine Clearance [CrCl] ≥90 mL/min) received one colchicine 0.6 mg tablet on study day 1.
Eligibility criteria:
Inclusion Criteria:

Adult males and females 18-70 years old with a body mass index of <39 kg/m^2.
Patients with normal renal function or mild renal impairment should be generally healthy on the basis of medical history and physical exam.
Patients with moderate to end stage renal impairment should be generally medically healthy other than with respect to the morbidities associated with impaired renal function.
Non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures).

Exclusion Criteria:

Known hypersensitivity to colchicine or any component of the formulation of the study drug.
Patients with a history or presence of a significant medical condition that would interfere with interpretation of the study results.
Patients who have used any drugs or substances known to inhibit or induce cytochrome P450 (CYP) enzymes and/or P-glycoprotein within 28 days prior to the first dose and throughout the study.
Patients with recent (2 year) history or evidence of alcoholism or drug abuse or significant psychiatric disease.
Patients with chronic hepatic dysfunction.
Intervention: Colchicine
Trial phase: Phase 4
ATC code: M04AC01
SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Participants with mild renal impairment (estimated Glomerular Filtration Rate [eGFR] 60 to 89 mL/min) received one colchicine 0.6 mg tablet on study day 1.
Eligibility criteria:
Inclusion Criteria:

Adult males and females 18-70 years old with a body mass index of <39 kg/m^2.
Patients with normal renal function or mild renal impairment should be generally healthy on the basis of medical history and physical exam.
Patients with moderate to end stage renal impairment should be generally medically healthy other than with respect to the morbidities associated with impaired renal function.
Non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures).

Exclusion Criteria:

Known hypersensitivity to colchicine or any component of the formulation of the study drug.
Patients with a history or presence of a significant medical condition that would interfere with interpretation of the study results.
Patients who have used any drugs or substances known to inhibit or induce cytochrome P450 (CYP) enzymes and/or P-glycoprotein within 28 days prior to the first dose and throughout the study.
Patients with recent (2 year) history or evidence of alcoholism or drug abuse or significant psychiatric disease.
Patients with chronic hepatic dysfunction.
Intervention: Colchicine
Trial phase: Phase 4
ATC code: M04AC01
SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.
Eligibility criteria:
Inclusion Criteria:

Adult males and females 18-70 years old with a body mass index of <39 kg/m^2.
Patients with normal renal function or mild renal impairment should be generally healthy on the basis of medical history and physical exam.
Patients with moderate to end stage renal impairment should be generally medically healthy other than with respect to the morbidities associated with impaired renal function.
Non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures).

Exclusion Criteria:

Known hypersensitivity to colchicine or any component of the formulation of the study drug.
Patients with a history or presence of a significant medical condition that would interfere with interpretation of the study results.
Patients who have used any drugs or substances known to inhibit or induce cytochrome P450 (CYP) enzymes and/or P-glycoprotein within 28 days prior to the first dose and throughout the study.
Patients with recent (2 year) history or evidence of alcoholism or drug abuse or significant psychiatric disease.
Patients with chronic hepatic dysfunction.
Intervention: Nicotine
Trial phase: Not Applicable
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 41
Group description: 1 administration of 1 mg
Eligibility criteria:
Inclusion Criteria:

Healthy smokers, smoking at least 15 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria:

Pregnancy, lactation or intended pregnancy.
Treatment with an investigational product or donation or loss of blood within 3 months preceding the first dose of study medication.
Intervention: Nicotine
Trial phase: Not Applicable
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 42
Group description: 2 administrations of 1 mg
Eligibility criteria:
Inclusion Criteria:

Healthy smokers, smoking at least 15 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria:

Pregnancy, lactation or intended pregnancy.
Treatment with an investigational product or donation or loss of blood within 3 months preceding the first dose of study medication.
Intervention: Nicotine
Trial phase: Not Applicable
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 43
Group description: 4 administrations of 1 mg
Eligibility criteria:
Inclusion Criteria:

Healthy smokers, smoking at least 15 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria:

Pregnancy, lactation or intended pregnancy.
Treatment with an investigational product or donation or loss of blood within 3 months preceding the first dose of study medication.
Intervention: Nicotine
Trial phase: Not Applicable
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 42
Group description: One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes
Eligibility criteria:
Inclusion Criteria:

Healthy smokers, smoking at least 15 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria:

Pregnancy, lactation or intended pregnancy.
Treatment with an investigational product or donation or loss of blood within 3 months preceding the first dose of study medication.
Intervention: Nicotine
Trial phase: Not Applicable
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Oral Nicotine 24 mg, 2 1mg self-administrations once every hour; 12 doses of 2 mg over 11 hours
Eligibility criteria:
Inclusion Criteria:

Healthy smokers, smoking at least 20 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria:

Pregnancy, lactation or intended pregnancy.
Treatment with an investigational product or donation or loss of blood within 3 month preceding the first dose of study medication.
Prior regular use of nicotine mouth spray
Intervention: Nicotine
Trial phase: Not Applicable
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 37
Group description: Oral Nicotine 24 mg, 2 1mg administrations by study personnel once every hour; 12 doses of 2 mg over 11 hours
Eligibility criteria:
Inclusion Criteria:

Healthy smokers, smoking at least 20 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria:

Pregnancy, lactation or intended pregnancy.
Treatment with an investigational product or donation or loss of blood within 3 month preceding the first dose of study medication.
Prior regular use of nicotine mouth spray
Intervention: Nicotine
Trial phase: Not Applicable
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 36
Group description: Oral Nicotine 48 mg, 2 1mg administrations by study personnel once every 30 minutes; 24 doses of 2 mg over 11.5 hours
Eligibility criteria:
Inclusion Criteria:

Healthy smokers, smoking at least 20 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria:

Pregnancy, lactation or intended pregnancy.
Treatment with an investigational product or donation or loss of blood within 3 month preceding the first dose of study medication.
Prior regular use of nicotine mouth spray
Intervention: Nicotine
Trial phase: Not Applicable
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 35
Group description: NiQuitin™ lozenge 4 mg; 12 doses of NiQuitin™ lozenge 4 mg over 11 hours
Eligibility criteria:
Inclusion Criteria:

Healthy smokers, smoking at least 20 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria:

Pregnancy, lactation or intended pregnancy.
Treatment with an investigational product or donation or loss of blood within 3 month preceding the first dose of study medication.
Prior regular use of nicotine mouth spray
Intervention: Nicotine
Trial phase: Not Applicable
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 35
Group description: 12 doses of NICORETTE® gum 4 mg over 11 hours
Eligibility criteria:
Inclusion Criteria:

Healthy smokers, smoking at least 20 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria:

Pregnancy, lactation or intended pregnancy.
Treatment with an investigational product or donation or loss of blood within 3 month preceding the first dose of study medication.
Prior regular use of nicotine mouth spray
Intervention: Laquinimod
Trial phase: Phase 2
ATC code: N07XX10
SMILES: CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: Participants received 2 capsules of laquinimod 0.5 mg orally once daily for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Participants diagnosed with SLE.
Participants with active lupus arthritis as evident by at least 4 tender and 4 swollen joints at screening and baseline visits, and moderate or severe arthritis with active synovitis in at least 1 joint, with some loss of functional range of movement present at screening and baseline visits.

Exclusion Criteria:

The participant's estimated glomerular filtration rate (eGFR) was less than or equal to 30 milliliters (mL)/minute/1.73 square meter (m^2), as calculated by the Modification of Diet in Renal Disease (MDRD) formula at the screening visit.
Participants with severe, unstable and/or progressive central nervous system (CNS) lupus and/or associated with significant cognitive impairment (upon the investigators' judgement).
Participants with a clinically significant or unstable medical or surgical condition that, in the investigator's opinion, would preclude safe and complete study participation.
Women who are pregnant or nursing or who intend to be during the study period.
Women of child-bearing potential who do not practice an acceptable method of birth control.
Intervention: Lidocaine
Trial phase: Not Applicable
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 53
Group description: Each participant was randomly assigned to receive this preparation during one of two consecutive intravitreal injection (if unilateral disease) or in one eye if requiring bilateral injections given on the same day. This method involved application of 0.5% proparacaine and then 3.5% ophthalmic lidocaine gel to the injection site.
Eligibility criteria:
Inclusion Criteria:

Has required repeat Ranibizumab injections and has had at least 3 injections prior to recruitment
Informed consent
Age ≥ 18 years
Clinical need for a therapeutic ranibizumab intravitreal injection regardless of the medical indication
Able to understand and read English

Exclusion Criteria:

Pregnancy (positive pregnancy test)
Mental disability
Prisoners
Patients with fluctuating or impaired decision-making capacity
Inability to comply with study or follow-up procedures
Previous reaction to the same drug class
Intervention: Chirhostim
Trial phase: Phase 3
SMILES: CC(C)CC(NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(N)Cc1c[nH]cn1)C(C)O)C(C)O)C(=O)NC(C(N)=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 64
Group description: Human Secretin for Injection 0.1 mL/kg IV
Eligibility criteria:
Inclusion Criteria:

Documented or suspected diagnosis of chronic pancreatitis or suspected diagnosis of pancreatic cancer.
Undergoing Endoscopic Procedure.
Age ≥ 18 years.
Willing and able to sign informed consent, meeting IRB guidelines.
Willing and able to meet all study requirements and obligations.

Exclusion Criteria:

Ongoing, active pancreatitis at the time of the procedure.
Known adverse reaction to secretin.
Recent (within one month) use of medication that can potentially cause pancreatitis, such as metronidazole, tetracycline, sulfonamides.
Use of anticholinergic medication within 7 days of study.
Pregnant women, nursing mothers, or women of childbearing potential not employing appropriate contraception. Acceptable methods of birth control are: intrauterine device, implantable progesterone device, progesterone intramuscular injection, oral contraceptive (started at least one month prior to Visit 1 and continuing for the duration of the trial), contraceptive patch, condoms with spermicide or abstinence.
Any medical condition which in the judgment of the Principal Investigator makes participation of the patient in the study medically unwarranted.
Known complete obstruction of the pancreatic duct.
Patients who have received an investigational product/drug or device within 30 days prior to Visit 1.
Intervention: Bupivacaine
Trial phase: Not Applicable
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: This group will receive bupivacaine (10ml of 0.5%) administered directly into the surgical wound at the iliac crest bone harvest site.

Bupivacaine: Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.
Eligibility criteria:
Inclusion Criteria:

patients 18 years of age or older undergoing posterior cervical, thoracic, or lumbar surgery
willingness to participate in the study.

Exclusion Criteria:

individuals who underwent surgical intervention in the past 6 months
previous iliac crest bone harvesting
history of tumor and spondyloarthropathies (rheumatoid arthritis, seronegative arthritis)
history of adverse reaction to local anesthetic
history of severe pelvic and hip conditions that can interfere with the outcome assessment of the study
opioid addiction
pregnancy
acute mental illness
uncontrolled major depression and any other psychiatric disorders
prisoners
non-english speaking patients
inability to understand the informed consent and demands of the study.
Intervention: Leuprolide
Trial phase: Phase 2
ATC code: L02AE02 | L02AE51
SMILES: CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) prior to radical prostatectomy.
Eligibility criteria:
Inclusion Criteria:

Histological proof of prostatic adenocarcinoma via a minimum of 6 core biopsy samples
Clinical stage T1c or T2 with high-grade disease (Gleason's 8-10) on initial biopsy, or clinical stage T2b-T2c with Gleason's grade >/= 7 and PSA > 10ng/ml.
No evidence of metastatic disease as determined by CT scans and bone scans.
Eastern Cooperative Oncology Group (ECOG) Performance Status of </= 1
Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (ANC) > 1,500 and platelet count of > 100,000.
Normal pituitary and adrenal function
Patients should be deemed to be candidates for radical prostatectomy.

Exclusion Criteria:

Histological variants in the primary tumor (histological variants other than adenocarcinoma); neuroendocrine tumor
Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
Uncontrolled hypertension
Abnormal Liver function
Active or symptomatic viral hepatitis or chronic liver disease
Clinically significant heart disease
Other active malignancy
History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
Previous treatment with abiraterone acetate
Patients who are not appropriate surgical candidates for radical prostatectomy
Prior chemotherapy or radiation therapy for prostate cancer.
Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study

Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
Intervention: Ketamine
Trial phase: Phase 1 | Phase 2
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
Eligibility criteria:
Inclusion Criteria:

Patients meeting the ACCP/ SCCM definition of severe sepsis will be enrolled in the study. These patients should have a known or suspected source of infection.
Patients within 12 hours of the development of one or more organ dysfunctions

Patients must exhibit 3 or more of the following signs of clinical inflammation:

Core temperature < 36ºC or > 38ºC.
Heart rate of 90 or greater not explained by another medical condition.
A respiratory rate of > 20 min-1, a PaCO2 < 32min-1 or the need for mechanical ventilation.
A white blood cell count of < 4000 cell/ml or > 12000 cells/ml or a WBC showing greater then 10% immature neutrophils.

Exclusion Criteria:

pregnant
increased intracranial pressure or closed head injury
history of psychotic mental disease
receiving Continuous Veno - Venous Hemofiltration